Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Accounts Payables (2022 - 2026)

Kura Oncology has reported Accounts Payables over the past 5 years, most recently at $7.0 million for Q1 2026.

  • Quarterly Accounts Payables fell 84.38% to $7.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.0 million through Mar 2026, down 84.38% year-over-year, with the annual reading at $5.0 million for FY2025, 241.52% up from the prior year.
  • Accounts Payables was $7.0 million for Q1 2026 at Kura Oncology, up from $5.0 million in the prior quarter.
  • Over five years, Accounts Payables peaked at $45.1 million in Q1 2025 and troughed at $1.5 million in Q4 2024.
  • The 5-year median for Accounts Payables is $2.7 million (2023), against an average of $8.0 million.
  • Year-over-year, Accounts Payables skyrocketed 839.02% in 2024 and then plummeted 84.38% in 2026.
  • A 5-year view of Accounts Payables shows it stood at $1.5 million in 2022, then surged by 50.03% to $2.3 million in 2023, then crashed by 36.13% to $1.5 million in 2024, then soared by 241.52% to $5.0 million in 2025, then skyrocketed by 40.38% to $7.0 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Accounts Payables are $7.0 million (Q1 2026), $5.0 million (Q4 2025), and $4.7 million (Q3 2025).